A little more than a year after taking on the role, the CEO of Editas Medicines is preparing to pass the torch, continuing a series of executive changes at the gene editing company.
Effective June 1, Jim Mullen will be replaced by Gilmore O’Neill, who most recently served as the chief medical officer at another company heavily invested in gene therapy research, Sarepta Therapeutics. Mullen isn’t cutting ties with Editas, though. He will stay on as executive chairman of the company’s board of directors, a position he held before and during his time as CEO.
“Unlike some of the things that we’ve seen in the past, this is a very mindful, thoughtful transition,” said Mullen, in an interview.
Editas hit a major milestone while under Mullen’s leadership, producing data from the first clinical trial of a treatment made with CRISPR gene editing technology that works inside the body. Yet Editas, like many of its peers, has also seen its stock price fall significantly over the past year. Though investors have pulled back from the biotechnology sector on a broad scale, the impact has appeared particularly large among genetic medicine developers.
Despite its status as one of the most advanced CRISPR-focused biotechs, departures and arrivals have been fairly commonplace in Editas’ top ranks over the past several years. Executives overseeing scientific research, finance and clinical development programs have left. And two months ago, the shake-ups continued with the firing of the company’s chief medical officer, Lisa Michaels.
Editas has also had three different CEOs since 2014. Mullen, who took the reins from Cynthia Collins last February, had previously held the same position at Biogen as well as Patheon, the contracted drug manufacturer bought by Thermo Fisher. READ MORE
by Jacob Bell
Source: biopharmadive.com
Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.
GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.
Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.
